Glutamate

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

Retrieved on: 
Tuesday, July 20, 2021
Branches of biology, Psychoactive drugs, Neurochemistry, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, Neurotransmitters, NMDA receptor, N-Methyl-D-aspartic acid, Ketamine

Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement.

Key Points: 
  • Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement.
  • Arbormentis LLC is a privately-held drug discovery company engaged in potentially transformative innovations for CNS diseases.
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Aptinyx to Participate in William Blair Biotech Focus Conference 2021

Retrieved on: 
Monday, July 12, 2021
Biotechnology, Pharmaceutical, Health, Branches of biology, Biology, Glutamate, Cell signaling, NMDA receptor, Neuroplasticity

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion at the William Blair Biotech Focus Conference on Thursday, July 15 at 12:00 p.m.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion at the William Blair Biotech Focus Conference on Thursday, July 15 at 12:00 p.m.
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment.

Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

Retrieved on: 
Tuesday, July 6, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Biology, Cell signaling, Glutamate, NMDA receptor

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on Tuesday, July 13 at 3:40 p.m.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on Tuesday, July 13 at 3:40 p.m.
  • A live webcast of the event will be available to clients of Cowen.
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.

Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

Retrieved on: 
Monday, June 7, 2021
Branches of biology, Glutamate, Biology, NMDA receptor antagonists, Molecular neuroscience, Ionotropic glutamate receptors, NMDA receptor, N-Methyl-D-aspartic acid

An archived replay of the event will be available for one year after the conclusion of the presentation.

Key Points: 
  • An archived replay of the event will be available for one year after the conclusion of the presentation.
  • Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

XWPharma Announces Abstract for XW10172 Accepted for Presentation at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Branches of biology, Sleep disorders, Glutamate, Neurochemistry, Psychoactive drugs, General anesthetics, Neurotransmitters, Amphetamine, Narcolepsy, gamma-Hydroxybutyric acid, Excessive daytime sleepiness, AMPA

The drug and formulation are designed to deliver oxybate without the sodium content of other products that is associated with increased cardiovascular health risk and monitoring requirements.

Key Points: 
  • The drug and formulation are designed to deliver oxybate without the sodium content of other products that is associated with increased cardiovascular health risk and monitoring requirements.
  • XWPharma's expertise in drug design is focused on providing potential first- and best-in-class medicines with differentiated features to address the unmet medical needs of patients suffering from debilitating neurological diseases.
  • XW10172 is a clinical-stage conjugate of the GABAB agonist, oxybate, in development as an investigational once-nightly therapy intended to regulate the patient\xe2\x80\x99s sleep cycle in order to alleviate excessive daytime sleepiness and other consequences of sleep dysfunction associated with neurodegenerative diseases, including Parkinson\xe2\x80\x99s disease and narcolepsy.
  • XW10508 is a glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy with potential abuse deterrent properties, designed for the treatment of major depressive disorder and chronic pain.\n"

Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021

Retrieved on: 
Thursday, May 6, 2021
Branches of biology, Drugs, NMDA receptor antagonists, Psychoactive drugs, Glutamate, Ionotropic glutamate receptors, Cell signaling, NMDA receptor, N-Methyl-D-aspartic acid, Forward-looking statement, Ketamine, Channel blocker

Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.

Key Points: 
  • Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • No forward-looking statement can be guaranteed, and actual results may differ materially from those projected.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021

Retrieved on: 
Saturday, May 1, 2021
Branches of biology, Drugs, Psychoactive drugs, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, General anesthetics, Nicotinic antagonists, NMDA receptor, Ketamine, N-Methyl-D-aspartic acid, Antidepressant

In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.

Key Points: 
  • In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.
  • The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

Retrieved on: 
Thursday, April 29, 2021
Biotechnology, Nanotechnology, Pharmaceutical, Health, Medical devices, Technology, Clinical trials, Other Health, Branches of biology, Biology, Neuroscience, Neural circuits, Neurophysiology, Neuroplasticity, Neurology, Glutamate, NMDA receptor, Neuron, Synaptic plasticity

ET to report first quarter 2021 financial results and discuss recent business highlights.\nTo access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 3628539.

Key Points: 
  • ET to report first quarter 2021 financial results and discuss recent business highlights.\nTo access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 3628539.
  • A live audio webcast of the event will be available on the Investors & Media section of Aptinyx\xe2\x80\x99s website at https://ir.aptinyx.com .
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate\xe2\x80\x94rather than block or over-activate\xe2\x80\x94NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment.

Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting

Retrieved on: 
Thursday, April 29, 2021
Branches of biology, Drugs, Psychoactive drugs, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, General anesthetics, Nicotinic antagonists, NMDA receptor, Ketamine, N-Methyl-D-aspartic acid, Antidepressant

In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.

Key Points: 
  • In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.
  • The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Psychoactive drugs, Drugs, NMDA receptor antagonists, Glutamate, Molecular neuroscience, Antidepressants, Ionotropic glutamate receptors, NMDA receptor, N-Methyl-D-aspartic acid, Ketamine

The webcast will be available for 90 days after the presentation.\nRelmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).

Key Points: 
  • The webcast will be available for 90 days after the presentation.\nRelmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).
  • Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.